Relevant bibliographies by topics / PEG 8 000

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'PEG 8 000'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'PEG 8 000.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "PEG 8 000"

1

Douer, Dan, Ibrahim Aldoss, Matthew A. Lunning, Laleh Ramezani, Patrick Burke, Lisa Mark, Janice Vrona, et al. "Pharmacokinetics-Based Modification of Intravenous Pegylated Asparaginase Dosing in the Context of a “Pediatric-inspired” Protocol in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)." Blood 120, no. 21 (November 16, 2012): 1495. http://dx.doi.org/10.1182/blood.v120.21.1495.1495.

Full text
Abstract:
Abstract Abstract 1495 Prolonged Asparaginase (ASP) use is standard in all pediatric ALL regimens. In adults ASP is either not used or given for much shorter duration. Recently, several adult ALL protocols adopted pediatric regimens, with long duration of ASP, mostly E. coli, with better outcomes than historically reported. However, optimal implementation of pediatric regimens to adults, especially ASP dosing, has not been studied, considering its potential higher toxicity. We report the results of an ALL protocol adopted from pediatrics, modified by using the long acting pegaspargase (PEG-ASP) with a pharmacokinetics-based dosing strategy, intended for adults with newly diagnosed ALL. Methods: We adopted the augmented BFM pediatric protocol (Nachman NEJM 1998) replacing the native E. coli ASP with 6 doses of PEG-ASP. Pediatric and most pediatric-inspired adult protocols use 2,500 u/m2 PEG-ASP at 2 week intervals. Based on our PEG-ASP adult PK and PD data (Douer Blood 2007), the dose was reduced to 2,000 u/m2IV, at intervals no shorter than 4 weeks. Other modifications include 1) Each PEG-ASP dose, having a very long activity (2–4 weeks), was synchronized with the time of myelosuppressive drugs so that there anticipated different serious toxicities are less likely to coincide. 2) Replaced escalated MTX dosing plus E.coli ASP with 4 fixed high doses of MTX, timing PEG-ASP to avoid its overlapping long enzymatic activity with MTX activity. 3) hydrocortisone pre-medication and steroids for 7–14 days after each PEG-ASP dose to prevent allergic reactions. The protocol included 8 cycles of multi-agent chemotherapy, 2-year maintenance and IT MTX CNS prophylaxis. PEG-ASP was given intravenously (IV) once on day 15–17 of induction phase I (cycle 1), induction phase II (cycle 2), two cycles of consolidation (# 3 & 6), and two cycles of delayed re-induction (# 5 & 8). Results: Between July 2004 and July 2009, 51 (17 women) adults with newly diagnosed previously untreated ALL were enrolled in 2 USC affiliated hospitals. Patient characteristics include: median age - 33 (range18–57) yrs, precursor B cell - 46, T cell-5, Ph+ 11, and median WBC-14,500 (range 800-512, 000)/dL. Total number of PEG-ASP doses was: all 6 doses - 23 pts, 4 doses- 1 pt., 3– 7 pts. 2–9 pts, 1–11pts. Twenty eight (55%) pts. did not complete 6 PEG-ASP doses due to: allogeneic HSCT −8 pts, refusal −1pt., induction failure – 2pts, death in CR −3 pts., relapse- 4 pts; and PEG-ASP related toxicities: 11 (21%) pts: including pancreatitis −7pts, allergy −3 pts, DVT-1 pt (one pt. had pancreatitis and later transplanted). Among 51 pts PEG-ASP related grade 3/4 toxicities were: anaphylaxis-2 pts.(4%); pancreatitis-7 (14%) pts.; thrombosis-8(16%) (5 catheter-related); transaminitis −33(65%); high bilirubin −22 (43%); hyperglycemia-17(33%); high triglycerides −8(16%); fatigue-4(8%). Table I shows the rates of ASP related toxicities in 173 doses. All toxicities were reversible without any PEG-ASP-related deaths. Outcome data is shown in Table 2. Median follow up – 44 months Neutralizing antibodies measured in 247 serum samples from 34 pts. (33, 11 & 10 pts. after PEG-ASP doses # 1, 4, and 6 respectively) were detected in 1 patient Conclusion: Our rational modification of a pediatric protocol, in adult ALL (age <57 years), is feasible, has very high CR rate (98% by 4 weeks), 58% 7-years DFS, even without HSCT, and in line with reported results of other pediatric-inspired regimens. PEG-ASP toxicities were common but mostly manageable and reversible. Our study suggests the that standard PEG-ASP adult dose can be reduced to 2,000 u/m2 IV at intervals no less than 4 weeks without impairing overall outcome. Steroids may reduce clinical allergies, without masking silent neutralizing antibody formation. The concepts of this study, especially PEG-ASP dosing, could be applied in future ALL protocols. Disclosures: Douer: Sigma Tau: Research Funding, Speakers Bureau. Avramis:Sigma Tau: Consultancy.
APA, Harvard, Vancouver, ISO, and other styles
2

McNiece, Ian, Roy Jones, Scott I. Bearman, Pablo Cagnoni, Yago Nieto, Wilbur Franklin, John Ryder, et al. "Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer." Blood 96, no. 9 (November 1, 2000): 3001–7. http://dx.doi.org/10.1182/blood.v96.9.3001.

Full text
Abstract:
Abstract Ex vivo expanded peripheral blood progenitor cells (PBPCs) have been proposed as a source of hematopoietic support to decrease or eliminate the period of neutropenia after high-dose chemotherapy. CD34 cells were selected from rhG-CSF mobilized PBPCs from patients with breast cancer and were cultured for 10 days in defined media containing 100 ng/mL each of rhSCF, rhG-CSF, and PEG-rhMGDF in 1 L Teflon bags at 20 000 cells/mL. After culture the cells were washed and reinfused on day 0 of transplantation. On day +1, cohort 1 patients (n = 10) also received an unexpanded CD34-selected PBPC product. These patients engrafted neutrophils (absolute neutrophil count, &gt;500/μL) in a median of 6 (range, 5-14) days. Cohort 2 patients (n = 11), who received expanded PBPCs only, engrafted neutrophils in a median of 8 (range, 4-16) days. In comparison, the median time to neutrophil engraftment in a historical control group of patients (n = 100) was 9 days (range, 7-30 days). All surviving patients are now past the 15-month posttransplantation stage with no evidence of late graft failure. The total number of nucleated cells harvested after expansion culture was shown to be the best predictor of time to neutrophil engraftment, with all patients receiving more than 4 × 107 cells/kg, engrafting neutrophils by day 8. No significant effect on platelet recovery was observed in any patient. These data demonstrate that PBPCs expanded under the conditions defined can shorten the time to engraftment of neutrophils compared with historical controls and that the rate of engraftment is related to the dose of expanded cells transplanted.
APA, Harvard, Vancouver, ISO, and other styles
3

McNiece, Ian, Roy Jones, Scott I. Bearman, Pablo Cagnoni, Yago Nieto, Wilbur Franklin, John Ryder, et al. "Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer." Blood 96, no. 9 (November 1, 2000): 3001–7. http://dx.doi.org/10.1182/blood.v96.9.3001.h8003001_3001_3007.

Full text
Abstract:
Ex vivo expanded peripheral blood progenitor cells (PBPCs) have been proposed as a source of hematopoietic support to decrease or eliminate the period of neutropenia after high-dose chemotherapy. CD34 cells were selected from rhG-CSF mobilized PBPCs from patients with breast cancer and were cultured for 10 days in defined media containing 100 ng/mL each of rhSCF, rhG-CSF, and PEG-rhMGDF in 1 L Teflon bags at 20 000 cells/mL. After culture the cells were washed and reinfused on day 0 of transplantation. On day +1, cohort 1 patients (n = 10) also received an unexpanded CD34-selected PBPC product. These patients engrafted neutrophils (absolute neutrophil count, >500/μL) in a median of 6 (range, 5-14) days. Cohort 2 patients (n = 11), who received expanded PBPCs only, engrafted neutrophils in a median of 8 (range, 4-16) days. In comparison, the median time to neutrophil engraftment in a historical control group of patients (n = 100) was 9 days (range, 7-30 days). All surviving patients are now past the 15-month posttransplantation stage with no evidence of late graft failure. The total number of nucleated cells harvested after expansion culture was shown to be the best predictor of time to neutrophil engraftment, with all patients receiving more than 4 × 107 cells/kg, engrafting neutrophils by day 8. No significant effect on platelet recovery was observed in any patient. These data demonstrate that PBPCs expanded under the conditions defined can shorten the time to engraftment of neutrophils compared with historical controls and that the rate of engraftment is related to the dose of expanded cells transplanted.
APA, Harvard, Vancouver, ISO, and other styles
4

Auger, Sophie, Philippe Quittet, Marie Cecile Bozonnat, Salahedine Bouya, Tarik Kanouni, Nathalie Fegueux, Patrice Ceballos, Jean-Côme Meniane, Guillaume Cartron, and Jean-Francois Rossi. "Febrile Neutropenia, Mucositis and Duration of Hospitalization Are Reduced After Pegfilgrastim Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Malignant Lymphopathies: Report of 683 PBSCTs From a Single Institution." Blood 114, no. 22 (November 20, 2009): 3410. http://dx.doi.org/10.1182/blood.v114.22.3410.3410.

Full text
Abstract:
Abstract Abstract 3410 Poster Board III-298 Granulocyte colony-stimulating factor (G-CSF) has been shown to decrease time to neutrophil recovery following PBSCT. Now, 3 products are available: 2 standard G-CSFs (filgrastim and lenograstim), and pegfilgrastim (PegG-CSF). In order to determine whether a single subcutaneous injection of Peg-G-CSF is as effective as a daily injection of standard G-CSF, in terms of haematological recovery, febrile neutropenic episodes (FN), antibiotic usage, hospitalization duration, mucositis, progressive free survival (PFS) and overall survival (OS), we retrospectively analyzed series of 558 patients having myeloma and lymphoma who underwent 683 PBSCT between 2000 and 2008 in our institution. Statistical analysis included univariate, Wilcoxon and χ2 fisher tests, logrank test for PFS and OS, and Cox model for multivariate analysis. From January 2000 and April 2005, 359 patients received standard G-CSF (filgrastim or lenograstim) and from May 2005 to December 2008, 298 patients received PegG-CSF. 26 patients did not receive G-CSF for any reasons. 427 PBSCTs have been performed for multiple myeloma (MM) after high dose melphalan, 197 for Non Hodgkin Lymphoma (NHL) and 59 for Hodgkin lymphoma (HL) with BEAM conditioning regimen. 133 patients underwent 2 or 3 PBSCT (130 MM and 3 HL). The mean of CD34 dose infused was 5.2 106 /kg (1.2-26.9) with 96% of the grafts containing more than 2.5 106 CD34/Kg. The median number of days of standard G-CSF given to reach an absolute neutrophil count (ANC) ≥500/ml was 9 days (0-29). Median time to neutrophil engraftment (ANC of 500/ml) was 11 days (5-30) in each group. The platelet recovery (platelet>20 000/mL) was 10 days (0-54) in each group. The platelet and RBC transfusion requirement are stastitically lower in the PegG-CSF than in the standard G-CSF group. As listed on the table, we have analyzed the following parameters for all patients: number of FN and their beginning and duration, number of antibiotic lines, duration of hospitalization, duration of mucositis, and the percentage of grade III and IV mucositis. Median, (range) Peg G-CSF standard G-CSF None G-CSF N 298 359 p 26 FN rate (%) 91.7 96.4 <0.01 96.16 Duration of FN (days) 2 (0-27) 2 (0-18) 0.62 2 (0-13) First day of FN (day) 5 (-3-16) 4 (-5-17) <0.01 4 (0-11) Number of antibiotic lines 1 (1-5) 2 (0-5) <0.01 3 (0-4) Duration of hospitalization (days) 17 (8-62) 19 (8-65) <0.01 24 (18-35) Duration of mucositis (days) 0 (0-75) 6 (0-60) <0.01 7.5 (0-10) Mucositis grade III, IV (%) 17.7 40.28 <0.01 ND The same significantly differences are observed in MM, NHL and HL patients. The use of standard G-CSF or PegG-CSF did not modify OS at 1 and 5 years for both NHL and HL patients. In MM population PFS was unmodified but OS appeared better in the PegG-CSF group compared to standard G-CSF: respectively 1 y OS at 1 year, 96% versus 92%, OS at 5 years: 79% versus 53% (p= 0.034). Such a difference could be explained by the early use of bortezomib regimen for induction therapy before PBSCT more frequently in PegG-CSF group and this feature has been analyzed. Among patients undergoing autologous stem cell transplantation the use of Peg G-CSF seems to show an advantage in terms of duration of hospitalization and reduce the percentage of grade III, IV mucositis and the number of febrile neutropenic episodes. Disclosures: No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
5

Wood, C. M., K. M. Gilmour, S. F. Perry, P. Part, and P. J. Walsh. "Pulsatile urea excretion in gulf toadfish (Opsanus beta): evidence for activation of a specific facilitated diffusion transport system." Journal of Experimental Biology 201, no. 6 (March 15, 1998): 805–17. http://dx.doi.org/10.1242/jeb.201.6.805.

Full text
Abstract:
When toadfish are made ureotelic by a crowding/confinement protocol, they excrete approximately 90 % of their urea nitrogen (urea-N) production in large, irregular pulses (1-2 pulses per day) from the gill region. We investigated three hypotheses as to the mechanism of pulsatile excretion: (i) the presence of an active reabsorptive 'back-transport' mechanism that is periodically inhibited to allow urea-N excretion to occur; (ii) the periodic occurrence of a generalized, non-specific increase in gill permeability; and (iii) the presence of a specific facilitated diffusion transport system that is periodically activated. Exposure of toadfish during non-pulse periods to treatments designed to block a 'back-transport' mechanism (Na+-free sea water or the urea analogues 30 mmol l-1 thiourea or 30 mmol l-1 acetamide in the external water) did not stimulate a leakage of urea-N, thereby opposing the first hypothesis. The second hypothesis was opposed by several results. Neither injection of the potent branchial vasodilator L-isoprenaline (10(-5) mol l-1) nor infusion of NH4Cl, the latter at levels known to stimulate urea-N efflux in perfused gills, had any effect on urea-N excretion. Furthermore, during natural pulse events, when the normally very low gill permeability to urea (3x10(-7) cm s-1) increased at least 35-fold, there was no accompanying increase in permeability to either 3H2O (1.5x10(-5) cm s-1) or the paracellular marker [14C]PEG-4000 (10(-8) cm s-1). However [14C]thiourea permeability (1.5x10(-7) cm s-1) increased approximately fivefold, in support of the third hypothesis. Furthermore, when 30 mmol l-1 urea was placed in the external water, a concentration (60 000 micromol-N l-1) approximately three times that of blood (20 000 micromol-N l-1), each efflux pulse event (measured with [14C]urea) was accompanied by a net uptake, such that blood urea-N levels rose rather than fell. A proportional 1:1 relationship between influx per unit external concentration and efflux per unit internal (i.e. plasma) concentration indicated a fully bidirectional transport system. The simultaneous presence of 60 mmol l-1 thiourea in the external water inhibited the influx component by 73 %, further supporting this conclusion. These data, together with recent molecular, morphological and endocrinological evidence, strongly suggest that pulsatile urea-N excretion is caused by the periodic activation of a facilitated urea transporter in the gills, similar to the vasopressin-regulated urea transporter in the mammalian kidney.
APA, Harvard, Vancouver, ISO, and other styles
6

Goekbuget, Nicola, Joachim Beck, Monika Brueggemann, Thomas Burmeister, Eike C. Buss, Norbert Frickhofen, Andreas Huettmann, et al. "Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)." Blood 120, no. 21 (November 16, 2012): 1493. http://dx.doi.org/10.1182/blood.v120.21.1493.1493.

Full text
Abstract:
Abstract Abstract 1493 Few older ALL pts are entered into prospective trials and data on characteristics and outcome are scarce. The GMALL started a prospective trial in older ALL (>55 yrs) in 2003. In Ph-neg ALL a prephase (Dexa, Cyclo, MTX i.th.) was followed by induction I (Dexa, VCR, Idarubicin), induction II (Cyclo, AraC), alternating consolidation with IDMTX (d 1,15) ×3, VM26/AraC ×2, reinduction (VCR, Ida, Cyclo, AraC) and maintenance (MP, MTX) up to 2 yrs. In CD20+ ALL Rituximab ×8 was added. CNS-prophylaxis consisted of i.th. triple combination (MTX, AraC, Dexa) ×4 during induction, ×8 during consolidation/maintenance. The original protocol (group 1) was amended to optimize CNS prophylaxis and consolidation (group 2). I.th. therapy was then performed with liposomal cytarabine, 3x during induction, 3x during consolidation. IDMTX dose was increased from 500 to 1000 mg/m2 and native E.coli ASP (10.000 U/m2) was added on d2 and d16 of IDMTX. VM26/AraC was replaced by IDAraC (1000 mg/m2 d1,3,5). In a further amendment the original i.th. prophylaxis was reinserted until final analysis of liposomal AraC became available. Furthermore, after induction, one cycle with pegylated ASP (500 U/m2) (PEG-ASP) was scheduled to evaluate feasibility in older pts (group 3). Results of induction were compared for groups 1–3; outcome analysis was restricted to 1–2 due to still short follow-up for group 3. 268 pts with a median age of 67 (55–85) yrs treated in 94 hospitals were evaluable (180, 43 and 45 pts in groups 1, 2 and 3 resp.). 39% were aged 55–65 yrs, 51% 66–75 yrs and 10% above 75 yrs. 67% had c/pre-B-ALL, 18% pro-B-ALL and 15% T-ALL. WBC was >30/nL in 27%. Poor ECOG status (≥2) before (ECOGb) or after (ECOGa) onset of ALL was described in 7% or 38% resp. 78% had any comorbidity and 9% had a Charlson score (ChS) ≥3. No significant differences were detected between groups 1–3. Overall 76% (N=203) achieved CR after induction, 14% experienced early death (ED) and 10% did not achieve CR. In groups 1–3 CR rates were 72%, 86% and 82% resp. and ED rates 18%, 0% and 11% resp. (p=.03). CR rates were 84%, 74% and 52% in three age groups (p=.002) with ED rates of 7%, 14% and 37% resp. (p=.0004). Immunophenotype and WBC (<> 30.000) correlated with CR but not ED rate. ECOGb 0–1 vs ≥2 correlated with CR (82% vs 33%;p<.0001) and ED (7% vs 53%;p<.0001). Also ECOGa correlated with CR (85% vs 67%;p=.003) and ED (6% vs 19%;p=.003). CR and ED rates were not influenced by comorbidity itself but by ChS < vs ≥3: CR (78% vs 59%;p=.003) and ED (11% vs 33%;p=.0007). Multivariate analysis confirmed ECOGb, WBC and age for CR rate, and ECOGb, age and ChS for ED. Overall survival (OS) at 5 yrs was 23%; 33% at 2 yrs for group 1 and 52% for group 2 resp. (p=.01). Mortality in CR was 6% and 15% of the pts were withdrawn in CR. Probability of continuous complete remission (CCR) was 32% at 5 yrs, 42% and 43% at 2 yrs for group 1 and group 2 resp. (p=>.05). Age (42% vs 37% vs 8%;p=.0007), WBC (43% vs 15%;p<.0006), ECOGb (40% vs 14%;p=.0008) and ECOGa (42% vs 30%;p=.0023) were correlated with OS in contrast to comorbidity and ChS. Age, treatment group, WBC, ECOGb and ECOGa were confirmed in multivariate analysis. Pts younger than 75 yrs with ECOGb below 2 had an 86% CR rate with 10% ED and 36% OS at 3 yrs. WBC and MRD were significant prognostic factors for CCR. MRD results after consolidation I were available in 33 pts. CCR was 11% in molecular failure vs 68% in molecular CR. Preliminary results confirmed feasibility of PEG-ASP. With this age adapted regimen a favorable CR rate was achieved in a large patient group with a median age of 67 yrs. CR was increased (86%) and mortality was decreased (0%) significantly with liposomal cytarabine compared to triple i.th. prophylaxis during induction, since the latter probably induced more bone marrow toxicity. Reduced ED contributed considerably to improved OS. Moderate intensive consolidation was feasible and ASP, including PEG-ASP, was well tolerated. Age was correlated with outcome and 75 yrs appears to be the upper limit for this regimen. General condition was an additional highly relevant prognostic factor whereas comorbidity, measured by Charlson score was associated with ED but not with OS. These results encourage further treatment optimisation in older ALL pts, including those with comorbidities, based on comprehensive diagnostics, geriatric assessment, MRD evaluation, intensified consolidation, use of ASP, dose-reduced stem cell transplantation and integration of new, targeted drugs. Disclosures: Goekbuget: Medac: Consultancy, Research Funding, Speakers Bureau; Novartis: Research Funding; BMS: Research Funding; Genzyme: Research Funding; Mundipharma: Research Funding, Speakers Bureau; Glaxo: Research Funding, Speakers Bureau; Micromet/AMGEN: Consultancy; Sigma Tau: Consultancy. Off Label Use: Liposomal cytarabine in prophylaxsis of CNS relapse in ALL.
APA, Harvard, Vancouver, ISO, and other styles
7

Hamurcu, Zuhal, Nazmi Saritas, Gulden Baskol, and Nese Akpinar. "Effect of Wrestling Exercise on Oxidative DNA Damage, Nitric Oxide Level and Paraoxonase Activity in Adolescent Boys." Pediatric Exercise Science 22, no. 1 (February 2010): 60–68. http://dx.doi.org/10.1123/pes.22.1.60.

Full text
Abstract:
The objective of the current study is to determine the effects of regular wrestling exercise oxidative DNA damage and antioxidant parameters. The findings of the current study have shown that 8-hydroxy-2’-deoxyguanosine (8-OHdG) obtained from wrestlers in basal status were significantly lower than those of sedentary (p = .001). In contrast, Nitric oxide (NO) and Paraoxonase-1 (PON1) were remarkably higher in wrestlers in basal status than those of sedentary (respectively, p = .001, p = .024). While the NO of wrestlers increased immediately after a 1.5-h exercise compared with those before exercise (p = .002), no differences was found between before and immediately after a 1.5-h exercise in 8-OHdG and PON1 (respectively, p = .777, p = .408).Statistically significant correlations were found between the NO and PON1 in the wrestlers in basal status (r = .671, p = .002). In conclusion, our study suggests that wrestling exercise for a healthy life is important in that it reduces DNA damage as well as enhancing antioxidant parameters.
APA, Harvard, Vancouver, ISO, and other styles
8

Gilreath, Jeffrey A., Tsewang Tashi, Soo Jin Kim, Kimberly Hickman, and Josef T. Prchal. "Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys®." Blood 132, Supplement 1 (November 29, 2018): 5459. http://dx.doi.org/10.1182/blood-2018-99-116852.

Full text
Abstract:
Abstract Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms (MPN) associated with morbidity and mortality resulting from thrombosis or transformation to myelofibrosis and/or secondary acute leukemia. The acquired somatic mutation JAK2V617Fhas been observed in 98% of PV patients, and around 50% of ET patients. Interferon is known to be an effective treatment for chronic MPNs, but unlike hydroxyurea (HU, Hydrea®), it has been shown to target the malignant clone by decreasing JAK2V617Fallelic burden, and in some patients restoring polyclonal hematopoiesis. (Liu et al, Blood. 2003;101:3294-3301). The covalent binding of polyethylene glycol to the interferon molecule, through pegylation, prolongs the half-life by lowering the clearance of interferon, thereby extending the duration of its therapeutic effects, permitting less frequent administration and fewer side-effects. Currently, there are two commercially available pegylated interferons in the U.S., peginterferon alfa-2b (PEG-Intron®, Merck) and peginterferon alfa-2a (Pegasys®, PEG, Roche), both with heterogeneous pegylation with multiple pegylation sites. Ropeginterferon-alfa 2b/P1101 (ROPEG) is a novel longer acting mono-pegylated recombinant proline-interferon alfa-2b which has shown good efficacy in PV and has successfully completed a phase III trial in PV patients comparing it against HU (PROUD-PV study) in Europe (ASH2016 Abstract;Blood. 2016;128:475). Earlier, we had enrolled 53 high risk PV and ET patients to the Myeloproliferative Disorders Research Consortium (MPD-RC) trials #111 (refractory to HU) and #112 (randomized to HU vs PEG)(www.clinicaltrials.gov; NCT01259856 and NCT01259817). After the completion of these trials, PEG was no longer supplied by the study and not adequately covered by insurance for many of our patients. Therefore, ROPEG was procured under an FDA-approved expanded access program and used as a substitute for those controlled on PEG, and these patients are being transitioned from PEG to ROPEG according to the dosing strategy shown in Table 1. Seven patients have been switched onto ROPEG as of writing this abstract (Table 2). After a mean follow-up of roughly 8 weeks (range: 2 - 10 weeks), all have maintained response to therapy and none have had a thrombotic event or new or increased interferon-related side effects thus far. Patient 002 experienced elevated AST/ALT while on PEG, which normalized after four q2 week doses of ROPEG (8 weeks of therapy). Patients 003 and 004 who had persistent fatigue on PEG, saw significant improvement of their symptoms after switching to ROPEG. In patient 005 who has ET, bone marrow cytogenetics at entry to PEG had a paracentric inversion of the long arm of chromosome 3, namely 3q21.3q26.2 (RPN1/MECOM, inv3; diagnostic of AML per WHO criteria), in 16/20 (80%) metaphases. Over the 4 ensuing years while on PEG, this cytogenetic abnormality progressively decreased. FISH assay was set up 2 years ago wherein 86/200 cells (46%) were positive with lowest achieved level of 36/200 cells (18%) without any evidence of emerging AML. Upon transition to ROPEG (2 fortnightly injections of 50 mcg), this response was maintained (23/200 cells scored (11.5%). Of the 3 patients who were JAK2V617Fpositive, one patient (patient 003) showed a decrease in the JAK2V617Fallelic burden (37% to 18%) after two months of ROPEG despite decreasing the dose to 50 mcg (from 100 mcg) 2 weeks after the first injection, while the other two patients had no statistically significant change in their JAK2V617Fallelic burden. Clonality will be followed in female subjects to see if clonal hematopoiesis is suppressed and normalizes with long-term administration of ROPEG. Our early experience suggests ROPEG is a safe and effective alternative to PEG permitting less frequent administration for patients with high risk PV and ET. Notable observations include normalization of hepatic transaminases previously induced by PEG, maintenance or even suppression of one highly deleterious cytogenetic abnormality, maintenance of ET & PV remission, and amelioration of interferon side-effects with lower equivalent doses. In the future, we intend to increase the pool of patients by designing a protocol for newly diagnosed high risk ET and PV with randomization to HU versus ROPEG. Disclosures No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
9

Bender, Matthew T., Robert W. Young, David A. Zarrin, Jessica K. Campos, Justin M. Caplan, Judy Huang, Rafael J. Tamargo, Li-Mei Lin, Geoffrey P. Colby, and Alexander L. Coon. "Twisting: Incidence and Risk Factors of an Intraprocedural Challenge Associated With Pipeline Flow Diversion of Cerebral Aneurysms." Neurosurgery 88, no. 1 (July 13, 2020): 25–35. http://dx.doi.org/10.1093/neuros/nyaa309.

Full text
Abstract:
Abstract BACKGROUND Pipeline Embolization Device (PED; Medtronic) “twisting” manifests with the appearance of a “figure 8” in perpendicular planes on digital subtraction angiography. This phenomenon has received little attention in the literature, requires technical precision to remediate, and has potential to cause ischemic stroke if not properly remediated. OBJECTIVE To report incidence, risk factors, and sequelae of PED twisting and to discuss techniques to remediate a PED twist. METHODS Case images were reviewed for instances of twisting from a prospectively-maintained, Institutional Review Board-approved cohort of patients undergoing flow diversion for cerebral aneurysm. RESULTS From August 2011 to December 2017, 999 PED flow diverting stents were attempted in 782 cases for 653 patients. A total of 25 PED twists were observed while treating 20 patients (2.50%, 25/999). Multivariate analysis revealed predictors of twisting to be: Large and giant aneurysms (odds ratio (OR) = 9.66, P = .005; OR = 27.47, P &lt; .001), increased PED length (OR = 1.14, P &lt; .001), and advanced patient age (OR = 1.07, P = .002). Twisted PEDs were able to be remediated 75% of the time, and procedural success was achieved in 90% of cases. PED twisting was not found to be a significant cause of major or minor complications. However, at long-term follow-up, there was a trend towards poor occlusion outcomes for the cases that encountered twisting. CONCLUSION Twisting is a rare event during PED deployment that was more likely to occur while treating large aneurysms with long devices in older patients. While twisting did not lead to major complications in this study, remediation can be challenging and may be associated with inferior occlusion outcomes.
APA, Harvard, Vancouver, ISO, and other styles
10

Martino, Rosemary. "When to PEG?" Dysphagia 17, no. 3 (July 2002): 233–34. http://dx.doi.org/10.1007/s00455-002-0061-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "PEG 8 000"

1

Chlopková, Barbora. "Optimalizace izolace plazmidové DNA pomocí magnetických částic." Master's thesis, Vysoké učení technické v Brně. Fakulta chemická, 2019. http://www.nusl.cz/ntk/nusl-401929.

Full text
Abstract:
The theoretical part summarizes information on the isolation and purification of plasmid DNA and nucleic acids as. Plasmid DNA is often used in gene engineering as a vector for the transfer of a particular gene. Its insulation and transportation in sufficient quality is crucial for other processes associated with it. Isolation and survival of pDNA using magnetic carriers of different concentrations of PEG 8000 in combination with 1M NaCl was investigated in experimental parts. Furthermore, the isolation of pDNA using commercial kits was examined.
APA, Harvard, Vancouver, ISO, and other styles
2

Noreikienė, Jovita. "7 - 8 klasių moksleivių originalumo raiška per technologijų pamokas." Master's thesis, Lithuanian Academic Libraries Network (LABT), 2005. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2005~D_20050609_192035-80554.

Full text
Abstract:
The evaluation of originality becomes the priority in the abundant market of various things, services and ideas. In our modern surroundings we can find everything that could meet almost all our needs and fancies, so, very often, we have to make a well motivated personal decision. The increasing demand for originality requires a deeper understanding of it. The main objective of this study is to find out what properties reflect the originality of ideas, things and activity and how children (teenagers) express their originality stepping into the world of adults. Expression of originality of 7 - 8 form students during the technology lessons was chosen as a subject matter of originality research, because the program of technological subjects (nutrition, textile, construction materials) give an opportunity to develop the expression of originality of students not only in the technological activity, but also to form their inclination to originality in private life, meeting the everyday demands for food, clothes, living space and communication. After generalization of analysis of scientific literature was disclosed the model of the meaning of originality. The following three main indicators are characteristic to originality, as the main aspect of creative activity: novelty, truthfulness and peculiarity. It also became clear that originality as a characteristic of a creative personality can be achieved by any individual. The teenager period is particularly favorable for developing... [to full text]
APA, Harvard, Vancouver, ISO, and other styles
3

Kaps, Lisa. "Verarbeitung des relativen Belohnungswertes im menschlichen Gehirn. Eine Metaanalyse hirnbildgebender Studien." Doctoral thesis, 2012. http://hdl.handle.net/11858/00-1735-0000-0006-B2CF-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Neumann, Angelika. "Einfluss von Aussaatstärke, Bodenbearbeitung und Anbaumuster auf den Ertrag von Erbsen-Hafer-Gemengen." Doctoral thesis, 2010. http://hdl.handle.net/11858/00-1735-0000-0006-B056-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "PEG 8 000"

1

Bares, Roland B., and Giovanni Lucignani, eds. Clinical PET. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0309-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sobic Saranovic, Dragana, Mariza Vorster, Sanjay Gambhir, and Thomas Neil Pascual, eds. PET/CT in Tuberculosis. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-47009-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dierckx, Rudi A. J. O., Andreas Otte, Erik F. J. de Vries, Aren van Waarde, and Adriaan A. Lammertsma, eds. PET and SPECT of Neurobiological Systems. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-53176-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Coniglio, Maria Anna, Cristian Fioriglio, and Pasqualina Laganà. Non-Intentionally Added Substances in PET-Bottled Mineral Water. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39134-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Glasper, Edward Alan, Gillian McEwing, and Jim Richardson, eds. Mental health. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780198569572.003.0022.

Full text
Abstract:
Anorexia nervosa 734Bulimia nervosa 736Enuresis 738Encopresis 740Depression 742Deliberate self-harm 744Challenging behaviour 746Attention deficit-hyperactivity disorder (ADHD) 748Autism 750Anxiety 752Conduct/antisocial disorder 754Substance misuse 756• Incidence: 0.8–8 in 100 000 individuals per year.• Peak age of onset: 15–19 years....
APA, Harvard, Vancouver, ISO, and other styles
6

Nolan, Jerry P. Advanced life support. Edited by Neil Soni and Jonathan G. Hardman. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199642045.003.0091.

Full text
Abstract:
Anaesthetists have a central role in cardiopulmonary resuscitation (CPR). The incidence of treated out-of-hospital cardiopulmonary arrest is 40 per 100 000 population and is associated with a survival rate to hospital discharge of 8–10%. The incidence of in-hospital cardiac arrest (IHCA) is 1–5 per 1000 admissions and is associated with a survival rate to hospital discharge of 13–17%. The most effective strategy for reducing mortality from IHCA is to prevent it occurring by detecting and treating those at risk or to identify in advance those with no chance of survival and to make a decision not to attempt resuscitation. The European Resuscitation Council and the Resuscitation Council (UK) publish guidelines for CPR every 5 years and the evidence supporting these is described in the international consensus on CPR science. The advanced life support algorithm forms the core of the guidelines but the precise interventions depend on the circumstances of the cardiac arrest and the skills of the healthcare providers. High-quality CPR with minimal interruptions will optimize survival rates. Shockable rhythms are treated with defibrillation while minimizing the pause in chest compressions. Although adrenaline (epinephrine) is used in most cardiac arrests, no studies have shown that it improves long-term outcome. The post-cardiac arrest syndrome is common and requires multiple organ support in an intensive care unit. Therapy in this phase is aimed at improving neurological (e.g. targeted temperature management) and myocardial (e.g. percutaneous coronary intervention) outcomes. Based on standard outcome measurements (e.g. cerebral performance category), 75–80% of survivors will have a ‘good’ neurological outcome, but many of these will have subtle neurocognitive deficits.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "PEG 8 000"

1

Adams, Hadie, Angelos G. Kolias, Adel Helmy, Peter J. A. Hutchinson, and Randall M. Chesnut. "Surgical management of head injury." In Oxford Textbook of Neurological Surgery, edited by Ramez W. Kirollos, Adel Helmy, Simon Thomson, and Peter J. A. Hutchinson, 509–20. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198746706.003.0043.

Full text
Abstract:
Traumatic brain injury (TBI) is a significant cause of preventable morbidity and mortality in the United Kingdom and across the world, leading to disability and loss of productivity. The estimated incidence of TBI in Europe is on average 235 per 100 000, ranging of 150–300/100 000 per year. The Glasgow Coma Scale (GCS) is often used to classify the severity of TBI, with patients scoring 8 or less being classified as severe, 9–12 as moderate, and scores of 13–15 as mild. Mild TBI is the most common form of head injury, and the incidence of TBI is the highest in young adult males. In Western countries the major causes of TBI-related hospitalizations are falls, assaults, and motor vehicle traffic collisions.
APA, Harvard, Vancouver, ISO, and other styles
2

"8. Dialectics of Enlittlement." In Think, Pig!, 108–23. Fordham University Press, 2020. http://dx.doi.org/10.1515/9780823270880-009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hilton-Jones, David, and Jacqueline Palace. "Disorders of the neuromuscular junction." In Oxford Textbook of Medicine, 5177–84. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199204854.003.2423_update_002.

Full text
Abstract:
Two fundamentally different pathological processes are associated with disease at the neuromuscular junction: (1) acquired disorders in which autoantibodies are directed against nerve or muscle receptor or ion channels; (2) rare inherited conditions in which the defect may be pre- or postsynaptic. Aetiology and epidemiology—the fundamental disorder is loss of functional acetylcholine receptors most frequently as a result of binding of anti-acetylcholine receptor (anti-AChR) antibodies. Incidence is about 10 per million population and prevalence about 8 per 100 000, with a marked female bias in cases aged under 40 years and male preponderance in those over 50 years. Thymomas occur in about 10% of cases....
APA, Harvard, Vancouver, ISO, and other styles
4

"8. At Last the Culprit: Melamine." In Pet Food Politics, 63–68. University of California Press, 2019. http://dx.doi.org/10.1525/9780520941984-009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brusa, Elisabetta. "Trasformazioni." In 8 tesi per 150 anni. Venice: Edizioni Ca' Foscari, 2019. http://dx.doi.org/10.30687/978-88-6969-384-7/001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"1 Dipartimento di Economia • 1913. Un Turco a Venezia." In 8 tesi per 150 anni. Venice: Edizioni Ca' Foscari, 2019. http://dx.doi.org/10.30687/978-88-6969-384-7/002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"2 Dipartimento di Studi Linguistici e Culturali Comparati • Aú… úúy!... Cuác? Cuác! Hipa! Upa! … ad Honorem Hombre 1972/2016." In 8 tesi per 150 anni. Venice: Edizioni Ca' Foscari, 2019. http://dx.doi.org/10.30687/978-88-6969-384-7/003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"3 Dipartimento di Scienze Molecolari e Nanosistemi • Dateci un atomo e noi coloreremo il mondo." In 8 tesi per 150 anni. Venice: Edizioni Ca' Foscari, 2019. http://dx.doi.org/10.30687/978-88-6969-384-7/004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"4 Dipartimento di Filosofia e Beni Culturali • Ca’FFFé? Eureka! Ca’ Foscari Fucine in Férmento." In 8 tesi per 150 anni. Venice: Edizioni Ca' Foscari, 2019. http://dx.doi.org/10.30687/978-88-6969-384-7/005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"5 Dipartimento di Studi sull’Asia e sull’Africa Mediterranea • …i fiocchi di neve parevano danzare nello spazio…" In 8 tesi per 150 anni. Venice: Edizioni Ca' Foscari, 2019. http://dx.doi.org/10.30687/978-88-6969-384-7/006.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "PEG 8 000"

1

Tonkin, KS, AA Joy, SK Basi, D. Fenton, J. Amanie, JR Mackey, K. Tankel, J. Deschenes, and S. Mcewan. "Abstract PD05-04: The Potential of Using Discordance of Estrogen PET (FES-PET) and Glucose PET (FDG-PET) Scans and Pathologic Characteristics Including HER2 and Ki67 To Predict for Hormone Insensitivity in Women with Metastatic Breast Cancer." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-pd05-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Goedjen, J. G., and G. P. Wagner. "Evaluation of Commercial Coatings on MarM-002, IN-939 and CM-247 Substrates." In ASME 1996 International Gas Turbine and Aeroengine Congress and Exhibition. American Society of Mechanical Engineers, 1996. http://dx.doi.org/10.1115/96-gt-458.

Full text
Abstract:
As part of the U.S. Department of Energy Advanced Turbine Systems Program, the performance of Chromalloy RT122, RT122 over RT69 and the Howmet 150L bond coats were evaluated for use in the next generation of Westinghouse combustion turbines. Air plasma sprayed and electron beam physical vapor deposition 8% yttria stabilized zirconia thermal barrier coatings were applied to the bond coats. The coating systems were evaluated in air at 2102°F (1150°C), cooling to room temperature once per day. The life-limiting failure mode in both air plasma sprayed (APS) and electron beam - physical vapor deposition (EB-PVD) coating systems is the oxidation of the bond coat. The coating life is related to the growth rate and morphology of the thermally grown oxide. The superior performance of RT122 on MarM-002, the duplex bond coat system of RT122 over RT69 on MarM-002 and Howmet 150L on MarM-002 can be related to the development of a uniform, slow growing oxide scale. The development of a non-uniform oxidation front contributes to the reduced life of RT122 on IN-939 and CM-247.
APA, Harvard, Vancouver, ISO, and other styles
3

Anheden, Marie, and Andrew R. Martin. "Thermodynamic Performance Analysis and Economic Evaluation of Externally Fired Gas Turbine Cycles for Small Scale Biomass Cogeneration." In ASME Turbo Expo 2000: Power for Land, Sea, and Air. American Society of Mechanical Engineers, 2000. http://dx.doi.org/10.1115/2000-gt-0016.

Full text
Abstract:
Externally fired gas turbine (EFGT) cycles in combination with a biomass-fueled, atmospheric circulating fluidized bed (CFB) furnace are investigated for small scale production of power and district heat. Both closed and open gas turbine cycle configurations are considered. The thermodynamic performance analysis includes an evaluation of cycle-to-furnace heat matching and cycle-side pressure loss considerations. An economic analysis is presented for the various EFGT configurations, and comparisons are made with existing and emerging alternatives for small-scale biomass cogeneration. Simulation results show that thermodynamic performance varies between the different configurations and working fluids, with electric efficiencies in the range of 31–38% (LHV) and total efficiencies of 86–106% (LHV). An economic evaluation for an 8 MWf plant shows that the specific capital cost is about 3200–3900 $/kWe for a first commercial plant. The turbomachinery and the CFB furnace dominate the total plant cost, with each contributing about 1/3 of the total installed equipment cost. The cost of electricity, COE, is estimated to be 73–84 $/MWhe for 4 000 full load hours per year in a cogeneration application.
APA, Harvard, Vancouver, ISO, and other styles
4

Dinesh, A., VK Ramteke, J. Chander, M. Tripathi, and S. Mahajan. "Abstract P4-02-02: Comparison of 18F-FDG PET-CT and 11C-MET PET-CT for assessment of response to neoadjuvant chemotherapy in locally advanced breast carcinoma." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p4-02-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Schindler, L., J. Moosbauer, G. Bernhardt, D. Hellwig, and M. Keller. "Ga-68 labeling of stable neurotensin(8-13) analogs via carbamoylated arginine residues gives NTS 1 R PET ligands with promising in vitro profile." In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708265.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ni Mhuircheartaigh, NM, M. Kell, FL Flanagan, GC Hargaden, HM Fenlon, TF Gorey, M. Stokes, RR Salman, and CS Smith. "Abstract P5-01-04: Preoperative PET-CT Staging of Axillary Node Positive Breast Cancer." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p5-01-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Xie, X., C. Bartholomeusz, DS Maxwell, Z. Peng, A. Kazansky, WG Bornmann, and NT Ueno. "Abstract P6-15-20: Development of PEA-15-Based Therapy in Breast Cancer in a Preclinical Study." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p6-15-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lee, J.-H., G.-T. Son, J.-E. Choi, S.-H. Kang, and S.-J. Lee. "Abstract P3-03-02: The metastatic rate of IMLN, when IMLN metastasis is suspected with PET CT." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p3-03-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Niikura, N., C. Costelloe, JE Madewell, N. Hayashi, T.-K. Yu, J. Liu, SL Palla, et al. "Abstract P5-01-02: Role of FDG-PET/CT in Metastatic Staging of Newly Diagnosed Primary Breast Cancer." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p5-01-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dintzis, SM, KH Allison, and RA Schmidt. "Abstract P3-10-34: HER2 Testing by FISH: Discordance between HER2 Signals Per Cell and HER2:CEP 17 Ratio." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p3-10-34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'PEG 8 000' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography